Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous heme arginate effects on MRI during ischemia
2008-006967-35Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of heme arginate in ischemia-reperfusion injury (IRI) and peripheral arterial disease (PAD), sponsored by Medical University of Vienna. Primary endpoints: Change in high-energy phosphate levels in ischemic skeletal muscle, Change in tissue pH in ischemic skeletal muscle and 2 more. Started Jan 2009; status: completed.
02
Drugs
heme arginate
03
Conditions
ischemia-reperfusion injury (IRI)peripheral arterial disease (PAD)
Beyond the preview
Go deeper on 2008-006967-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006967-35.